Ask most people what the open question on epithalon is and they'll say telomeres. It isn't. The bigger gap in epithalon research is more basic than mechanism: as far as we can find, nobody has ever published a human pharmacokinetic study of this peptide. No plasma concentration–time curve, no measured half-life in people, no tissue distribution data. Every dosing protocol circulating online — the ten-day courses, the 5–10mg cycles twice a year — sits on top of that void. If you're asking "what is epithalon" or "is epithalon legal in Australia", the pharmacokinetics question is the one that quietly determines whether any of the rest of it can be true.

This post looks at what's actually known about how epitalon behaves in a body, why a short-lived tetrapeptide is claimed to produce effects lasting months, and how that claim holds up against the 2025 independent laboratory data. Our full profile sits at /peptides/epithalon.

What is epithalon, and why the dosing question matters

Epithalon (also written epitalon, or AEDG) is a synthetic tetrapeptide — alanine-glutamic acid-aspartic acid-glycine — designed in the Soviet-era laboratory of Vladimir Khavinson to mimic the amino acid composition of Epithalamin, a bovine pineal gland extract. The two are not interchangeable: Epithalamin is a crude animal-derived extract containing many components, epitalon is four amino acids. Trials of one do not transfer to the other, and a great deal of online marketing blurs exactly that line.

A 2025 review in Molecules that catalogues 25 years of epitalon work makes an underappreciated admission: despite extensive study of the peptide's biological and pharmacodynamic effects, the physico-chemical and structural investigation of the molecule remains limited. Dosing regimens in the literature are described (roughly 0.1–10µg/day in rodents, commonly 0.5–1mg/day in the Russian human work), but plasma concentration data are not.

Free tetrapeptides are, as a class, degraded rapidly by peptidases in blood and tissue. Half-life figures for epitalon quoted on supplier and protocol pages range from "under five minutes" to "about thirty minutes" — a six-fold spread — and we could not trace either number to a published human study. That is the honest state of it: the numbers being used to justify injection schedules appear to originate somewhere other than measured human data.

The durability problem

Here is the tension at the centre of epithalon research. The peptide is claimed to be cleared from circulation within minutes, yet the Khavinson-lineage literature reports effects on melatonin rhythm and gene expression persisting for months after a single ten-day course.

That is not impossible. The proposed explanation from Khavinson's own group is epigenetic: that short peptides like AEDG penetrate the cell and nucleus and interact directly with DNA and histone proteins, switching gene expression patterns that then persist after the peptide is gone. The group's review of AEDG and neurogenesis sets out this model, drawing on in-silico modelling and cell and animal work.

Two things to hold at once. It is a coherent hypothesis, and it is the originating group's hypothesis, tested largely by the originating group, in preclinical systems. A mechanism that would explain the durability claim is not the same thing as evidence that the durability occurs in humans given a subcutaneous injection.

What the independent 2025 data can and can't tell you

The first substantive independent human-cell work came from Brunel University London in 2025, published in Biogerontology. Normal breast epithelial cells and fibroblasts, plus the 21NT and BT474 breast cancer lines, were treated with epitalon for four days. The team reported dose-dependent telomere lengthening: via hTERT and telomerase upregulation in the normal cells, and substantially via alternative lengthening of telomeres (ALT) in the cancer lines, with only minor ALT activity in normal cells.

That is a genuine and welcome replication signal, and the cancer-line finding is an open safety question rather than a settled one. But note the design in pharmacokinetic terms: cells sat in a dish, bathed continuously in a known concentration of peptide, for four days. Nothing about that experiment tells you whether an injected dose in a person ever reaches a nucleus at a comparable concentration, or for anything like as long. In-vitro exposure is not a dose.

It is also worth recording that in November 2025 the journal published a correction noting the wrong figures had appeared in Figures 1, 2 and 3 of the original paper. This is a figure-handling error, not a retraction, and the conclusions stand. But when an entire independent evidence base consists of a single paper, the robustness of that paper carries unusual weight.

The only recent human report we could find involving epitalon is an n-of-1 case report in which a patient with cognitive decline received epitalon alongside Semax, therapeutic plasma exchange and umbilical-cord mesenchymal stem cell exosomes, over a year. Biological age fell by 7.9 years and telomere length moved from 6.45 to 6.59kb. Four concurrent interventions, one patient, no control: nothing here can be attributed to epitalon.

Epithalon in Australia: the regulatory position

Epithalon is not an approved medicine anywhere in the world — not in Australia, not in the United States, not in the European Union. In Australia it therefore falls into the TGA's unapproved therapeutic goods framework, and the TGA has been explicit and increasingly active about peptides in this category.

The TGA's guidance on importing, compounding and supplying unapproved peptide products states that such products have not been assessed for safety, quality or effectiveness, and that unknowns include how they are manufactured, whether they are sterile, how they behave in the body and what they actually contain. The regulator names BPC-157, GHK-Cu, TB-500, retatrutide and CJC-1295 as examples; epitalon is not on that list, but the framework is substance-agnostic. Advertising unapproved therapeutic goods to Australian consumers is generally unlawful, with civil penalties running to $1.82 million per breach for individuals.

Internationally, epitalon (free base) and epitalon acetate appeared on the agenda of the US FDA's Pharmacy Compounding Advisory Committee meeting on 23–24 July 2026, which considers substances for the 503A bulks list. That is a compounding-eligibility question, not a marketing approval, and a final FDA determination had not been published at the time of writing.

One further caution for anyone reading trial registries: registry entries for fashionable peptides are not automatically real studies. Check that the listed sponsor is a verifiable organisation before treating a record as evidence.

Where this leaves the dosing charts

The published epithalon dosing protocols are not derived from pharmacokinetic modelling. They are inherited from mid-2000s Russian clinical practice and then repeated. Until someone measures epitalon in human plasma and tissue, "5mg for ten days, twice yearly" is a convention, not a calculated dose — and any claim about what that schedule achieves in a body is inference stacked on inference.

Compare how other compounds in our peptides library are covered, and join the free updates list for new evidence as it lands.

FAQ

What is epithalon?

Epithalon (epitalon, AEDG) is a synthetic four-amino-acid peptide developed to mimic the composition of Epithalamin, a bovine pineal extract. It is investigational and not an approved medicine in any country.

Is epithalon legal in Australia?

Epithalon is not approved by the TGA as a medicine, so it falls under Australia's unapproved therapeutic goods rules. The TGA has an active compliance focus on the import, compounding, supply and advertising of unapproved peptide products.

What is the half-life of epithalon?

There does not appear to be a published human pharmacokinetic study. Figures quoted online range from under five minutes to about thirty minutes, and we could not trace them to primary human data.

Does epithalon actually lengthen telomeres?

An independent 2025 Brunel University study reported dose-dependent telomere lengthening in cultured human cells over four days, via telomerase in normal cells and ALT in breast cancer lines. That is cell-culture evidence only, and it has not been shown to translate to injected doses in people.

Sources

This article is independent information, not medical advice. Epithalon is an investigational compound not approved as a medicine in Australia or any other jurisdiction; retatrutide.net.au has no affiliation with any manufacturer or supplier.